Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fluent Corp. (CNTMF)
Miami, FL, US
Fluent Corp. is a comprehensive cannabis enterprise, managing all stages of its business from cultivation to retail, with licenses and active operations spanning Florida, Pennsylvania, New York, and Texas. It conducts business under its proprietary "Fluent" brand, aiming to be a premier provider of high-quality cannabis products and services for the communities it engages with. This ambition is underpinned by Fluent's unwavering pursuit of operational superiority across all key areas: growing, processing, logistics, and sales. The company's principal office is situated in Tampa, Florida. Its ordinary shares are publicly traded on the CSE as "TIUM.U" and on the OTCQB under the ticker "CNTMF." For additional corporate information, interested parties can visit www.investors.getfluent.com.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.70% | -0.40% | +6.56% | -28.57% | -38.42% | -50.10% | -50.00% | -68.75% | -97.77% | -98.59% | -98.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-16.3% Q1'26: -33.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+23.1% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-98.7% Q1'26: -17.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-54.8% Q1'26: -39.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-87.2% Q1'26: -68.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+96.9% Q1'26: +89.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-5.33× Q1'26: -14.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
28.51M
est: 30.00M (-5.0%)
|
52.39M
est: 57.15M (-8.3%)
|
65.44M
est: 79.00M (-17.2%)
|
87.69M
est: 88.00M (-0.4%)
|
97.29M
est: 95.00M (+2.4%)
|
103.56M
est: 106.00M (-2.3%)
|
86.69M
est: 119.00M (-27.2%)
|
| EBITDA |
-25.37M
est: 1.43M (-1,877.4%)
|
-8.18M
est: 2.72M (-400.6%)
|
6.74M
est: 3.76M (+79.2%)
|
2.86M
est: 4.19M (-31.6%)
|
23.90M
est: 4.52M (+428.8%)
|
1.31M
est: 1.93M (-32.3%)
|
-26.26M
est: 2.17M (-1,311.2%)
|
| EBIT |
-34.26M
est: -3.24M (-958.6%)
|
-16.45M
est: -6.16M (-166.9%)
|
1.85M
est: -8.52M (+121.7%)
|
3.86M
est: -9.49M (+140.6%)
|
8.83M
est: -10.25M (+186.1%)
|
-13.69M
est: -16.39M (+16.5%)
|
-47.50M
est: -18.40M (-158.1%)
|
| Net Income |
-53.23M
est: -64.03M (+16.9%)
|
-36.74M
est: -46.24M (+20.6%)
|
-19.00M
est: -32.02M (+40.6%)
|
-37.15M
est: -35.57M (-4.4%)
|
-22.75M
est: -7.11M (-219.8%)
|
-40.39M
est: -56.04M (+27.9%)
|
-72.50M
est: 56.04M (-229.4%)
|
| SGA |
41.05M
est: 12.35M (+232.3%)
|
32.12M
est: 23.53M (+36.5%)
|
30.05M
est: 32.52M (-7.6%)
|
27.41M
est: 36.23M (-24.3%)
|
30.95M
est: 39.11M (-20.9%)
|
36.81M
est: 40.27M (-8.6%)
|
39.38M
est: 45.21M (-12.9%)
|
| EPS |
-0.29
est: -0.18 (-61.1%)
|
-0.18
est: -0.13 (-38.5%)
|
-0.08
est: -0.09 (+7.7%)
|
-0.15
est: -0.10 (-50.0%)
|
-0.08
est: -0.02 (-300.0%)
|
-0.13
est: -0.08 (-62.5%)
|
-0.12
est: 0.08 (-250.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Pure Cannabis ETF YOLO | 0.41% | 131.3K | 0.91% |
| 2 | AdvisorShares Pure US Cannabis ETF MSOS | 0.01% | 64.8K | 0.81% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liora Boudin | Corporate Controller | 560.6K | female |
| Patricia Fonseca | Chief Financial Officer & Corporate Secretary | 392.8K | female |
| Samantha Senne | Executive Vice President of Operations | 334.2K | female |
| Victor Bindi | Chief Operating Officer | 319.9K | male |
| Christine Senne | Director of Compliance | 245.4K | — |
| Jeffrey Reath | Consultant | 197.9K | male |
| William Smith | Executive Chairman | 150.0K | male |
| Matt Mundy | Chief Legal Officer | — | male |
| Jennifer McCafferty-Fernandez | Chief Science Officer | — | — |
| David E. Vautrin | Interim Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNTMF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
